{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:06:04Z","timestamp":1758845164131},"reference-count":17,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2007,1,31]],"date-time":"2007-01-31T00:00:00Z","timestamp":1170201600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p> <jats:italic>\u03b2\u2010Blockers with pharmacologic effects that differ from conventional agents might add to antihypertensive treatment options. This study evaluated a new once\u2010daily formulation of the \u03b2\u2010\/\u03b1<jats:sub>1<\/jats:sub>\u2010blocker, carvedilol controlled\u2010release (CR), in hypertensive patients off treatment or while still taking up to 2 (non\u2010\u03b2\u2010blocker) agents. After a 4\u2010week run\u2010in phase, patients were randomized either to placebo (n=76) or carvedilol CR 20 mg (n=82), 40 mg (n=76), or 80 mg (n=86) once daily. After 6 weeks of treatment, ambulatory blood pressure monitoring was repeated to measure the primary end point of changes in mean 24\u2010hour diastolic blood pressure. During treatment, 24\u2010hour diastolic blood pressure fell in the placebo and carvedilol CR 20\u2010mg, 40\u2010mg, and 80\u2010mg groups by (mean + SE) 0.4\u00b10.9, 4.4\u00b10.9, 7.9\u00b10.9, and 9.6\u00b10.9 mm Hg, respectively (<\/jats:italic>P<jats:italic>\u2264.001, trend test for all carvedilol CR doses with placebo). Corresponding 24\u2010hour systolic blood pressure changes were 0.6\u00b11.4, 6.8\u00b11.3, 10.1\u00b11.4, and 12.5\u00b11.3 mm Hg, respectively (<\/jats:italic>P<jats:italic>\u2264.001, trend test). Diastolic blood pressure trough\u2010to\u2010peak ratios (placebo\u2010corrected) based on ambulatory blood pressure monitoring (trough = mean of 20\u2010 to 24\u2010hour post\u2010dose readings; peak = mean of 3\u2010 to 7\u2010hour post\u2010dose readings) for 20\u2010mg, 40\u2010mg, and 80\u2010mg doses were 0.73, 0.64, and 0.65, respectively. Adverse events, including clinical chemistry values, were similar in the drug\u2010treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose\u2010dependent antihypertensive effect that persists throughout a 24\u2010hour period.<\/jats:italic><\/jats:p>","DOI":"10.1111\/j.1524-6175.2006.05696.x","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T20:46:04Z","timestamp":1170449164000},"page":"840-849","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of a Once\u2010Daily Formulation of Carvedilol for the Treatment of Hypertension"],"prefix":"10.1111","volume":"8","author":[{"given":"Michael A.","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"C","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malini","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenic A.","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,31]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"417","volume-title":"Hypertension Primer","author":"Frishman WH","year":"2003"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000035653.72855.BF"},{"key":"e_1_2_7_4_2","first-page":"1205","volume-title":"Atherosclerosis and Coronary Artery Disease","author":"Frishman WH","year":"1996"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","year":"2003","journal-title":"JAMA"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67573-3"},{"issue":"1","key":"e_1_2_7_7_2","first-page":"S2","article-title":"Preclinical and clinical pharmacology of carvedilol","volume":"7","author":"Ruffolo RR","year":"1993","journal-title":"J Hum Hypertens"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000138616"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01409471"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1991.tb00698.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.suppl_F.38"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199302000-00006"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.18.2227"},{"key":"e_1_2_7_14_2","unstructured":"COREG (carvedilol) tablets [prescribing information]. GlaxoSmithKline 2005."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000187261.40190.2e"},{"key":"e_1_2_7_16_2","first-page":"377","volume-title":"Hypertension Primer","author":"Weber MA","year":"1999"},{"key":"e_1_2_7_17_2","first-page":"131","volume-title":"Cardiovascular Pharmacotherapeutics","author":"Sica DA","year":"2003"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7216-0258-5.50156-3"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-6175.2006.05696.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1524-6175.2006.05696.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:31:10Z","timestamp":1696973470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-6175.2006.05696.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1524-6175.2006.05696.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-6175.2006.05696.x","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}